Skye Bioscience (SKYE) Stock Statistics & Valuation Metrics

Skye Bioscience has a market cap or net worth of $79.34M. The enterprise value is $17.63.

Skye Bioscience has 4,427,676 shares outstanding. The number of shares has decreased by -2.65% in one year.

Skye Bioscience’s return on equity (ROE) is -2.79 and return on invested capital (ROIC) is -286.55%.

The current PE Ratio of Skye Bioscience is ―. Skye Bioscience’s PEG ratio is -0.00571.

In the last 12 months, Skye Bioscience had revenue of 0.00 and earned -55.92M in profits. Earnings per share was -11.28.

In the last 12 months, operating cash flow was -38.81M and capital expenditures -11.00, giving a free cash flow of -38.81M billion.

Skye Bioscience pays an annual dividend of ―, resulting in a dividend yield of ―

Skye Bioscience upcoming earnings date is Nov 5, 2026, After Close (Confirmed).

Skye Bioscience as a current ratio of 3.30, with Debt / Equity ratio of -7.18%

In the past 12 months, Skye Bioscience has paid 5.40K in taxes.

Skye Bioscience EV to EBITDA ratio is -0.44, with an EV/FCF ratio of -0.56.

Skye Bioscience has $10.06M in cash and marketable securities with $35.70K in debt, giving a net cash position of $10.03M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Skye Bioscience is ―, which is 11.43% higher than the current price. The consensus rating is ―